MGB Health Plan Drops Dana-Farber From Medicare Advantage Network, Disrupting Care for 1,000 Patients

Key points

• Effective October 1, 2026, Mass General Brigham Health Plan will exclude Dana-Farber Cancer Institute from its Medicare Advantage provider network.
• The plan serves roughly 20,500 members, but only a fraction receive cancer care at Dana-Farber; about 1,000 patients are directly impacted by the network removal.
• A 90-day transition period allows patients to continue current care, but coverage may end by early 2027 unless they switch plans or meet specific exceptions like active clinical trials.
• MGB Health Plan states the decision is due to challenging Medicare Advantage market conditions, not the separate clinical split between MGB and Dana-Farber scheduled for 2028.
• Patients like 88-year-old Eldon Clingan, who has seen the same oncologist for over 20 years, face uncertainty about medication costs and continuity of care.

Background

This development occurs amid a broader trend of hospital-owned insurance plans, or 'payviders,' reshaping Medicare Advantage markets. Recent industry shifts include Humana trimming its footprint to improve margins and Costco entering the Medicare space through partnerships. These moves highlight increasing financial pressures on Medicare Advantage plans, which often lead to network reductions to control costs and improve profitability.

How outlets are covering it

MGB Health Plan attributes the network change to nationwide Medicare Advantage market challenges, explicitly stating it is unrelated to the clinical separation between MGB and Dana-Farber. In contrast, CBS News and patient advocates frame the move as collateral damage from the hospital systems' split, emphasizing the emotional and practical burden on patients. STAT News provides the broader business context, noting the plan's 20,500 membership base, while UA.News reiterates the immediate impact on patients like Eldon Clingan. The Boston Globe, via STAT, highlights the tension between corporate financial decisions and patient continuity of care.

Why it matters

The removal of a major cancer institute from a Medicare Advantage network directly impacts patient access to specialized care, forcing elderly and chronically ill individuals to navigate complex insurance changes. This case illustrates the growing risks of payvider models, where hospital-owned insurance plans may prioritize financial sustainability over network stability, potentially fragmenting care for vulnerable populations.

What to watch

Patients affected by the network change must decide whether to switch insurance plans or find new oncologists before the 90-day transition period ends. MGB Health Plan may extend coverage for specific cases, such as ongoing clinical trials or radiation therapy, but most patients will face a hard deadline. The broader clinical split between MGB and Dana-Farber is scheduled for 2028, which may further complicate care coordination in Boston.